Aller au contenu principal
2014 article

Somatostatin receptors expression in normal prostate gland assessed by 68Ga-DOTATOC PET/CT

0Citations signalées, ce qui n’est pas une note de qualité
2Institutions déclarées
2Pays d’affiliation déclarés

Rattachement africain : rs, de. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

63 Objectives The aim was to investigate somatostatin receptor (sstr) expression in normal prostate by determining the maximum standardized uptake value (SUVmax) of 68Ga-DOTATOC PET/CT in neuroendocrine tumor (NET) patients, without NET involvement of the prostate gland, in order to establish the reference standard. Methods Sixty-four NET patients (24-97yrs, 60±14) underwent 68Ga-DOTATOC PET/CT. SUVmax of the prostate gland, normal liver, testes and gluteus muscles were evaluated. The prostate gland size was measured. Statistical analysis was performed using dedicated software (SPSS13). Results Two patients had normal size of the prostate gland, 33 slight prostate enlargement, 17 prostate hypertrophy, 10 prostate hyperplasia and two had concomitant prostate cancer. Mean/median 68Ga-DOTATOC SUVmax values were: normal prostate 2.6±0.0, slightly enlarged prostate 4.2±1.6, prostatic hypertrophy 4.9±1.6, prostatic hyperplasia 5.0±1.5, prostate cancer 9.5±2.1, normal liver 7.3±1.8, testes 1.8±0.5, gluteus 1.0±0.2. The normal prostate gland had 3 times less sstr expression than normal liver tissue. Strong correlation was found between patient age and sstr expression in prostate/prostate size. No significant difference existed in sstr expression between prostatic hypertrophy and hyperplasia. Conclusions Normal prostate tissue has very low sstr expression. Hypertrophic and hyperplastic prostate have higher sstr expression. Prostate hyperplasia and hypertrophy cannot be differentiated by 68Ga/DOTATOC PET/CT. Only concomitant prostate cancer in our group of patients was associated with higher sstr expression than the non-neoplastic liver tissue. Care should be taken not to overlook augmented 68Ga-DOTATOC uptake in the prostate gland of patients undergoing radiolabeled sst analogue PET/CT (especially if it is higher than in the liver tissue), which could indicate cancerous tissue.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

Aucun DOI disponible pour le contrôle Crossref.

Où se fait cette recherche

  • Centar za Promociju Nauke pays non établi dans la notice
    Organisme public
  • Zentralklinik Bad Berka pays non établi dans la notice
    Établissement de santé
  • Clinical Center of Serbia and Faculty of Medicine Center for Nuclear Medicine pays non établi dans la notice
    Université ou école supérieure
  • Theranostics Center for Molecular Radiotherapy and Imaging pays non établi dans la notice
    Institution

Centar za Promociju Nauke, Zentralklinik Bad Berka et Center for Nuclear Medicine — Clinical Center of Serbia and Faculty of Medicine, avec 1 autre affiliation.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsMedical Imaging and Pathology Studies

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.